{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-350537","form_type":"8-K","ticker":"APVO","cik":"0001671584","company_name":"Aptevo Therapeutics Inc.","filed_at":"2026-08-14T12:10:17+00:00","discovered_at":"2026-08-14T12:15:03.012671+00:00","generated_at":"2026-08-14T12:15:10.623666+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Aptevo Q2: mipletamig 81% remission in AML; Niowave 50/50 radiopharma deal","bullets":["Cash $9.8M at June 30, 2026; raised $0.6M under Yorkville SEPAs in Q2.","Mipletamig: 87% clinical benefit rate, 81% remission rate in 31 frontline AML patients; 55% MRD neg, 36% TP53, 6 bridged to transplant.","Appointed Mary J. Janatpour, Ph.D. as SVP and Chief Scientific Officer.","Secured $1.5M non-dilutive grant from Andy Hill CARE Fund for APVO451 IND-enabling work; candidate selection by year-end 2026.","Entered 50/50 collaboration with Niowave for up to three radiopharmaceutical programs; Niowave took 7.9% equity stake (up to 19.99%)."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-350537","json":"https://secwatch.observer/filing/0001193125-26-350537.json","markdown":"https://secwatch.observer/filing/0001193125-26-350537.md","text":"https://secwatch.observer/filing/0001193125-26-350537.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/0001193125-26-350537-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1671584/000119312526350537/apvo-20260814.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-14T12:15:10.623666+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}